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SUMMARY – The aim of this study was to investigate whether gestational diabetes mellitus 
(GDM) is associated with inflammation by comparing serum levels of human chitinase-3-like pro-
tein 1 (YKL-40), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR). This 
case control study included 29 pregnant women with GDM and 29 pregnant women with normal 
glucose tolerance matched for age (±2 years) and pre-pregnancy body mass index (±2 kg/m2). The 
YKL-40/CHI3L1 levels were measured, and NLR and PLR investigated. There were no statisti-
cally significant differences in maternal age, gestational age, gravidity and parity. Higher YKL-40 
levels were recorded in pregnant women with GDM compared to control subjects (203 (65-300) ng/
mL vs. 159.2 (14-290) ng/mL, p=0.007). NLR and PLR were significantly higher in GDM com-
pared with control group. In conclusion, GDM is associated with high levels of YKL-40, NLR and 
PLR, which indicate inflammatory status.
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Introduction
Gestational diabetes mellitus (GDM), developing 
in 6%-7% of pregnant women, is defined as carbo-
hydrate intolerance that begins or is first recognized 
during pregnancy1. Even though the association be-
tween inflammation and insulin resistance is well 
known, the data related to the role of inflammation in 
GDM are conflicting. In a recent study, Ozyer et al. 
revealed that maternal serum levels of inflammatory 
mediators were not related to GDM at the time of the 
glucose challenge test in the late second or early third 
trimester2.
A new biomarker, human chitinase-3-like protein 
1 (YKL-40), has been found to be elevated in can-
cer and inflammatory diseases3-5. Patients with type 
2 diabetes had elevated YKL-40 and high sensitivity 
C-reactive protein (hsCRP) levels, and it was related 
to insulin resistance4. According to the study by Kyr-
gios et al., serum levels of YKL-40 were elevated in 
obese youth and represented a marker of insulin resis-
tance even in childhood5. Schaller et al., on the other 
hand, disclosed that YKL-40 levels were not different 
between GDM and control patients either during or 
after pregnancy. The role of YKL-40 in GDM seems 
to require further evaluation6.
The neutrophil/lymphocyte ratio (NLR) and 
platelet/lymphocyte ratio (PLR) have been consid-
ered as systemic inflammatory response markers. Sefil 
et al. suggested that increased NLR might be associ-
ated with increased HbA1c in patients with type 2 
diabetes mellitus7.
This study aimed to evaluate whether GDM is as-
sociated with inflammation in terms of serum levels 
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of YKL-40 and NLR. To our knowledge, this is the 
first study investigating the relation of YKL-40, NLR 
and GDM.
Materials and Methods
This case control study was conducted in a tertia-
ry referral center, with approval of the Local Ethics 
Committee. Twenty-nine healthy pregnant women 
and 29 women with GDM having singleton pregnan-
cies, gestational age of 34 to 40 weeks, were included 
in the study. A history or new diagnosis of corticos-
teroid-treated asthma, liver disease, renal disease, 
Crohn’s disease, ulcerative colitis, celiac disease, and 
history of type 1 or type 2 diabetes were determined 
as the exclusion criteria. Twenty-nine pregnant wom-
en with normal glucose tolerance and 29 women with 
GDM were included in the control and case groups, 
respectively. Screening for GDM was conducted with 
the 50-g glucose loading test at 24th-28th week of ges-
tation. The threshold value of plasma glucose level 
to define an abnormal glucose challenge test result 
was 140 mg/dL. The patients with positive screen-
ing results underwent a 100-g oral glucose tolerance 
test (OGTT). GDM diagnosis was based on two or 
more values from a 3-hour 100-g OGTT meeting or 
exceeding the criteria developed by Carpenter and 
Coustan8: fasting >5.3 mmol/L; 1 hour >180 mg/dL; 
2 hours >155 mg/dL; 3 hours >140 mg/dL. Body mass 
index (BMI, kg/m2) was calculated in study subjects. 
The case and control groups were matched for age (±2 
years) and pre-pregnancy BMI (±2 kg/m2). Age, ges-
tational age, gravidity, and parity were recorded. 
The YKL-40/CHI3L1 levels were measured with 
the Human Chitinase-3-like Protein 1 (YKL-40/
CHI3L1) ELISA Kit, Catalog No. CSB-E13608h 
(96T) kit. Fibrinogen levels were evaluated by the He-
mosIL®, Fibrinogen-C XL (Catalog No. 0020003910) 
kit. Complete blood count analysis was performed at 
hematology laboratory within 2 hours of collection of 
blood samples on a Beckman Coulter Gen-S autoana-
lyzer (High Wycombe, UK). NLR was calculated by 
dividing absolute neutrophil count by absolute lym-
phocyte count and PLR was calculated by dividing 
platelet count by absolute lymphocyte count.
Statistical analyses were performed by the SPSS 
(Statistical Package for Social Sciences Inc., Chicago, 
IL, USA) for Windows 15.0 program. The normality 
of data distribution was determined by Kolmogorov-
Smirnov test. Continuous variables were presented as 
mean ± standard deviation (SD) and compared by us-
ing the t-test for independent samples when showing 
normal distribution. Mann-Whitney U test was used 
for results not displaying normal distribution or for 
comparison of nonparametric data. The strength of 
association between the variables was calculated us-
ing Pearson’s correlation test for parametric variables 
and Spearman Rho correlation test for nonparametric 
variables. The level of significance was set at p<0.05.
Results





Age (years)* 29.3±5.2 27.0±6.1 0.154
Body mass index (kg/m2)* 29.1±5.2 27.1±3.3 0.06
Gravidity** 3 (1-8) 2 (1-5) 0.086
Parity** 1 (0-5) 0 (0-4) 0.249
Gestational age (days)* 259±21 256±19 0.197
Neutrophil/lymphocyte ratio* 5.1±1.9 3.3±0.9 0.0001
Platelet/lymphocyte ratio* 144.7±48.3 114.4±40.4 0.018
YKL-40 (ng/mL)** 203 (65-300) 159.2 (14-290) 0.007
Fibrinogen (mg/dL)* 442.9±83.6 412.5±69.3 0.209
GDM = gestational diabetes mellitus; *values are mean ± standard deviation; **values are median (minimum-maximum); YKL-40 = human chitinase-
3-like protein 1; p<0.05 = level of statistical significance
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There were no statistically significant between-
group differences between the group according to 
maternal age, gestational age, gravidity, parity and 
BMI (Table 1). Higher YKL-40 levels (203 (65-300) 
ng/mL vs. 159.2 (14-290) ng/mL, p=0.007) were re-
corded in pregnant women with GDM as compared 
to control group (Fig. 1). NLR and PLR were signifi-
cantly higher in GDM compared with control group 
(Table 1).
No correlation was found between YKL-40 (r=-
0.172, p=0.210) and age, YKL-40 and BMI (r=-0.059, 
p=0.662), and YKL-40 and glucose levels (r=0.039, 
p=0.787).
Discussion
Gestational diabetes mellitus is associated with se-
rious maternal and fetal complications, among which 
unexplained stillbirth, an increased frequency of hy-
pertension, and the need for cesarean delivery can 
be included. These complications have a substantial 
economic impact, including costs of monitoring and 
treating sick mothers and neonates9,10. The pathophys-
iology of GDM deserves further evaluation. Segovia et 
al. have reported that inflammatory mediators might 
influence fetal adipose tissue, liver and skeletal mus-
cle, and lead to insulin resistance and GDM11. Ategbo 
et al. investigated circulating levels of cytokines and 
adipokines in 59 women with GDM, compared to 60 
age-matched controls12. In this study, adiponectin, 
interleukin (IL)-2 and interferon-γ were found to be 
decreased. Cytokines such as tumor necrosis factor-α 
and IL-6 were elevated in patients with GDM13.
Information on the physiological function and the 
mechanisms by which YKL-40 mediates its effects 
is still insufficient. In patients with type 2 diabetes, 
YKL-40 and hsCRP levels were found to be elevat-
ed, and this was associated with insulin resistance4. 
Hansen et al. report on patients with pancreatitis and 
secondary diabetes mellitus to have elevated levels of 
YKL-40 and IL-6 compared to healthy subjects, sug-
gesting that YKL-40 is not a primary mediator of dia-
betes mellitus but a consequence of the diabetic state3. 
According to Celik et al., plasma YKL-40 levels are 
increased in patients with polycystic ovary syndrome 
compared to healthy subjects14. 
Schaller et al., contrary to our results, revealed 
that YKL-40 was not different between GDM and 
controls either during or after pregnancy6. They sug-
gest that the absence of difference in YKL-40 levels 
between the GDM and control groups might be due 
to a similar inflammatory status at the time of mea-
surements and explain this finding by the short dura-
tion of metabolic changes during GDM, which was 
in contrast to the results in type 2 diabetes. However, 
the present study revealed that there was an associa-
tion between elevated YKL-40 levels and GDM. All 
studies investigating YKL-40 in diabetic patients 
point to the role of YKL-40 in the progression/prog-
nosis of patients with diabetes3-5.
We also found significantly higher NLR and PLR 
in GDM compared with the control group. To our 
knowledge, there is only one study investigating NLR 
in GDM15. Similar to our results, Yilmaz et al. showed 
increased NLR level to be a powerful and indepen-
dent predictor of GDM15.
In conclusion, GDM is associated with high levels of 
YKL-40, NLR and PLR, which indicate inflammatory 
status. As the number of studies on GDM increases, its 
association with inflammation will become clearer. 
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Fig. 1. Human chitinase-3-like protein 1 (YKL-40) 
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Sažetak
MOGUĆA POVEZANOST GESTACIJSKOG DIJABETESA S UPALOM 
A. Aktulay, Y. Engin-Ustun, M. Sahin Ozkan, S. Erkaya, M. Kara, O. Kaymak i N. Danisman
Cilj ovoga istraživanja bio je procijeniti je li gestacijski dijabetes melitus (GDM) udružen s upalom i to uspored-
bom serumskih razina humanog hitinazi-3-sličnog proteina 1 (YKL-40) te omjera neutrofila/limfocita (NLR) i omjera 
trombocita/limfocita (PLR). U ovo istraživanje parova bilo je uključeno 29 trudnica s GDM i 29 trudnica s normalnom 
tolerancijom glukoze. Dob (± 2 godine) i indeks tjelesne mase prije trudnoće bili su podjednaki u obje skupine. Mjerene 
su razine humanog hitinazi-3-sličnog proteina 1 (YKL-40/CHI3L1) te ispitani omjeri NLR i PLR. Nije bilo statistički 
značajnih razlika u dobi, gestacijskoj dobi i gravidnosti. Zabilježene su više razine YKL-40 u trudnica s GDM u usporedbi 
s kontrolnim trudnicama (203 (65-300) ng/mL prema 159,2 (14-290) ng/mL, p=0,007). NLR i PLR bili su značajno viši 
u skupini s GDM nego u kontrolnoj skupini. U zaključku, GDM je udružen s visokim razinama YKL-40, NLR i PLR 
koji ukazuju na upalno stanje.      
Ključne riječi: CHI3L1 protein, humani; Dijabetes, gestacijski; Leukociti, broj; Neutrofili – citologija; Limfociti – citologija; 
Trombociti – citologija  
